Visceral leishmaniasis elimination in India: progress and the road ahead

References

• Burza S, Croft SL, Boelaert M. Leishmaniasis. Lancet. 2018;392(10151):951–970.
   PubMed Web of Science ®Google Scholar
• Singh OP, Hasker E, Boelaert M, et al. Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination. PLoS Negl Trop Dis. 2020;14(8):e0008363.
   PubMed Web of Science ®Google Scholar
• Rijal S, Sundar S, Mondal D, et al. Eliminating visceral leishmaniasis in South Asia: the road ahead. Bmj. 2019;364:k5224.
   PubMedGoogle Scholar
• Le Rutte EA, Chapman LAC, Coffeng LE, et al. Elimination of visceral leishmaniasis in the Indian subcontinent: a comparison of predictions from three transmission models. Epidemics. 2017;18:67–80.
   PubMed Web of Science ®Google Scholar
• WHO. Leishmaniasis. https://www.who.int/news-room/fact-sheets/detail/leishmaniasis. (Ed.^(Eds) (WHO)
   Google Scholar
• Faber C, Montenegro Quiñonez C, Horstick O, et al. Indoor residual spraying for the control of visceral leishmaniasis: a systematic review. PLoS Negl Trop Dis. 2022;16(5):e0010391.
   PubMedGoogle Scholar
• World Health Organization (WHO). Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021–2030. Geneva:World Health Organization. 2020. Licence: CC BY-NC-SA 3.0 IGO. (Ed.^(Eds).
   Google Scholar
• Boelaert M, Meheus F, Sanchez A, et al. The poorest of the poor: a poverty appraisal of households affected by visceral leishmaniasis in Bihar, India. Trop Med Int Health. 2009;14(6):639–644.
   PubMed Web of Science ®Google Scholar
• Singh OP, Hasker E, Boelaert M, et al. Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis. 2016;16(12):e304–e309.
   PubMedGoogle Scholar
• Singh OP, Singh B, Chakravarty J, et al. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty. 2016;5:19.
   PubMed Web of Science ®Google Scholar
• Sundar S, More DK, Singh MK, et al. Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis. 2000;31(4):1104–1107.
   PubMed Web of Science ®Google Scholar
• Sundar S. Drug resistance in Indian visceral leishmaniasis. Trop Med Int Health. 2001;6(11):849–854.
   PubMed Web of Science ®Google Scholar
• Thakur CP, Kumar M, Pandey AK. Comparison of regimes of treatment of antimony-resistant kala-azar patients: a randomized study. Am J Trop Med Hyg. 1991;45(4):435–441.
   PubMed Web of Science ®Google Scholar
• Sundar S, Mehta H, Chhabra A, et al. Amphotericin B colloidal dispersion for the treatment of Indian visceral leishmaniasis. Clin Infect Dis. 2006;42(5):608–613.
   PubMed Web of Science ®Google Scholar
• Sundar S, Jha TK, Thakur CP, et al. Oral miltefosine for Indian visceral leishmaniasis. N Engl J Med. 2002;347(22):1739–1746.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh A, Rai M, et al. Efficacy of miltefosine in the treatment of visceral leishmaniasis in India after a decade of use. Clin Infect Dis. 2012;55(4):543–550.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J, Agarwal D, et al. Single-dose liposomal amphotericin B for visceral leishmaniasis in India. N Engl J Med. 2010;362(6):504–512.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. Leishmaniasis: an update of current pharmacotherapy. Expert Opin Pharmacother. 2013;14(1):53–63.
   PubMed Web of Science ®Google Scholar
• Sundar S, Chakravarty J. An update on pharmacotherapy for leishmaniasis. Expert Opin Pharmacother. 2015;16(2):237–252.
   PubMed Web of Science ®Google Scholar
• Hasker E, Malaviya P, Scholar VK, et al. Post kala azar dermal leishmaniasis and leprosy prevalence and distribution in the Muzaffarpur health and demographic surveillance site. PLoS Negl Trop Dis. 2019;13(10):e0007798.
   PubMed Web of Science ®Google Scholar
• Zijlstra EE. Precision medicine in control of visceral leishmaniasis caused by L. donovani. Front Cell Infect Microbiol. 2021;11:707619.
   PubMed Web of Science ®Google Scholar
• Le Rutte EA, Zijlstra EE, de Vlas SJ. Post-Kala-Azar dermal leishmaniasis as a reservoir for visceral leishmaniasis transmission. Trends Parasitol. 2019;35(8):590–592.
   PubMed Web of Science ®Google Scholar
• Gedda MR, Singh B, Kumar D, et al. Post kala-azar dermal leishmaniasis: a threat to elimination program. PLoS Negl Trop Dis. 2020;14(7):e0008221.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh OP, Chakravarty J. Visceral leishmaniasis elimination targets in India, strategies for preventing resurgence. Expert Rev Anti Infect Ther. 2018;16(11):805–812.
   PubMed Web of Science ®Google Scholar
• WHO. Leishmaniasis. (Ed.^(Eds) (2018)
   Google Scholar
• NVBDCP. Independent assessment of Kala-Azar elimination programme India. (Ed.^(Eds). 2019.
   Google Scholar
• NVBDCP. Kala-Azar situation in India. (Ed.^(Eds)
   Google Scholar
• Singh OP, Sundar S. Developments in diagnosis of visceral leishmaniasis in the elimination era. J Parasitol Res. 2015;239469. DOI:10.1155/2015/239469
   PubMedGoogle Scholar
• Thakur L, Singh KK, Shanker V, et al. Atypical leishmaniasis: a global perspective with emphasis on the Indian subcontinent. PLoS Negl Trop Dis. 2018;12(9):e0006659.
   PubMed Web of Science ®Google Scholar
• Sundar S, Singh OP. Molecular diagnosis of visceral leishmaniasis. Mol Diagn Ther. 2018;22(4):443–457.
   PubMed Web of Science ®Google Scholar
• Cloots K, Singh OP, Singh AK, et al. Assessing L. donovani skin parasite load: a proof of concept study of a microbiopsy device in an Indian setting. Front Cell Infect Microbiol. 2021;11:645121.
   PubMed Web of Science ®Google Scholar
• Cloots K, Marino P, Burza S, et al. Visceral leishmaniasis-HIV coinfection as a predictor of increased leishmania transmission at the village level in Bihar, India. Front Cell Infect Microbiol. 2021;11:604117.
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sanz MG, et al. HIV and visceral leishmaniasis coinfection in Bihar, India: an underrecognized and underdiagnosed threat against elimination. Clin Infect Dis. 2014;59(4):552–555.
   PubMed Web of Science ®Google Scholar
• Molina R, Canavate C, Cercenado E, et al. Indirect xenodiagnosis of visceral leishmaniasis in 10 HIV-infected patients using colonized Phlebotomus perniciosus. Aids. 1994;8(2):277–279.
   PubMed Web of Science ®Google Scholar
• Burza S, Mahajan R, Sinha PK, et al. Visceral leishmaniasis and HIV co-infection in Bihar, India: long-term effectiveness and treatment outcomes with liposomal amphotericin B (AmBisome). PLoS Negl Trop Dis. 2014;8(8):e3053.
   PubMed Web of Science ®Google Scholar
• Cloots K, Singh OP, Singh AK, et al. Diagnosis of visceral leishmaniasis in an elimination setting: a validation study of the diagnostic algorithm in India. Diagnostics (Basel). 2022;12(3). 10.3390/diagnostics12030670.
   PubMedGoogle Scholar
• Kushwaha AK, Scorza BM, Singh OP, et al. Domestic mammals as reservoirs for leishmania donovani on the Indian subcontinent: possibility and consequences on elimination. Transbound Emerg Dis. 2022;69(2):268–277.
   PubMed Web of Science ®Google Scholar
• Scorza BM, Mahachi KG, Cox AC, et al. Leishmania infantum xenodiagnosis from vertically infected dogs reveals significant skin tropism. PLoS Negl Trop Dis. 2021;15(10):e0009366.
   PubMed Web of Science ®Google Scholar
• Arumugam S, Scorza BM, Petersen C. Visceral leishmaniasis and the skin: dermal parasite transmission to sand flies. Pathogens. 2022;11(6):610.
   PubMed Web of Science ®Google Scholar
• Poche DM, Garlapati RB, Mukherjee S, et al. Bionomics of Phlebotomus argentipes in villages in Bihar, India with insights into efficacy of IRS-based control measures. PLoS Negl Trop Dis. 2018;12(1):e0006168.
   PubMed Web of Science ®Google Scholar
• Poche DM, Wang HH, Grant WE. Visceral leishmaniasis on the Indian Subcontinent: efficacy of fipronil-based cattle treatment in controlling sand fly populations is dependent on specific aspects of sand fly ecology. PLoS Negl Trop Dis. 2020;14(2):e0008011.
   PubMed Web of Science ®Google Scholar
• Murray HW, Berman JD, Davies CR, et al. Advances in leishmaniasis. Lancet. 2005;366(9496):1561–1577.
   PubMed Web of Science ®Google Scholar
• WHO. https://www.who.int/health-topics/neglected-tropical-diseases#tab=tab_1. (Ed.^(Eds)
   Google Scholar
• NLEP. Progress report for the year 2014-2015. Central Leprosy Division Directorate General of Health Services Nirman Bhawan, New Delhi. http://nlep.nic.in/pdf/Progress%20report%2031st%20March%202014-15%20-.pdf).
   Google Scholar
• Sachdeva S, Sood AK. Leprosy Elimination Monitoring (LEM) in India: a novel exercise of monitoring, learning, and capacity building. Indian J Commun Med. 2014;39(2):59–62.
   PubMedGoogle Scholar
• Badaro R, Jones TC, Lorenco R, et al. A prospective study of visceral leishmaniasis in an endemic area of Brazil. J Infect Dis. 1986;154:639–649.
   PubMed Web of Science ®Google Scholar
• Badaro R, Jones TC, Carvalho EM, et al. New perspectives on a subclinical form of visceral leishmaniasis. J Infect Dis. 1986;154:1003.
   PubMed Web of Science ®Google Scholar
• Ho M, Siongok TK, Lyerly WH, et al., Prevalence and disease spectrum in a new focus of visceral leishmaniasis in Kenya. Trans R. Soc. Trop. Med. Hyg. 1982;76:741–746.
   PubMed Web of Science ®Google Scholar
• Sacks DL, Lal SL, Shrivastava SN, et al. An analysis of T cell responsiveness in Indian Kala-azar. J Immunol. 1987;138:908–913.
   PubMed Web of Science ®Google Scholar
• Singh OP, Hasker E, Sacks D, et al. Asymptomatic Leishmania infection: a new challenge for leishmania control. Clin Infect Dis. 2014;58(10):1424–1429.
   PubMed Web of Science ®Google Scholar
• Cloots K, Uranw S, Ostyn B, et al. Impact of the visceral leishmaniasis elimination initiative on Leishmania donovani transmission in Nepal: a 10-year repeat survey. Lancet Glob Health. 2020;8(2):e237–e243.
   PubMed Web of Science ®Google Scholar